The authors compile and discuss study design data from ongoing clinical trials to address the key questions of ‘which’ tissue source, donor profile, isolation technique, culture conditions, long-term culture and cryopreservation for MSCs; the question of ‘when’ with regard to defining the transplantation window, by identifying and staging of patients based on their pro-inflammatory profile; and finally that of ‘how much’ with respect to the number of cells in a single administration, the number of doses and route of transplantation.
[Cytotherapy]
6807162
{6807162:FVXVKHP9}
apa
50
1
161870
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-c8eac0e4d8d2ae9c70b0b50db2a02bde%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22FVXVKHP9%22%2C%22library%22%3A%7B%22id%22%3A6807162%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Shahani%20and%20Datta%22%2C%22parsedDate%22%3A%222021-04-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EShahani%2C%20P.%2C%20%26amp%3B%20Datta%2C%20I.%20%282021%29.%20Mesenchymal%20Stromal%20Cell%20therapy%20for%20COVID-19%3A%20Which%3F%20When%3F%20And%20How%20Much%3F%20%3Ci%3ECytotherapy%3C%5C%2Fi%3E%2C%20%3Ci%3E0%3C%5C%2Fi%3E%280%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jcyt.2021.04.004%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jcyt.2021.04.004%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6807162%26amp%3Bitem_key%3DFVXVKHP9%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mesenchymal%20Stromal%20Cell%20therapy%20for%20COVID-19%3A%20Which%3F%20When%3F%20And%20How%20Much%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pradnya%22%2C%22lastName%22%3A%22Shahani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Indrani%22%2C%22lastName%22%3A%22Datta%22%7D%5D%2C%22abstractNote%22%3A%22%3Ch2%3EAbstract%3C%5C%2Fh2%3E%3Cp%3EMesenchymal%20Stromal%20Cells%20%28MSCs%29%20are%20under%20active%20consideration%20as%20a%20treatment%20strategy%20to%20control%20the%20hyperinflammation%20and%20slow%20disease%20progression%20in%20COVID-19.%20The%20possible%20mechanism%20of%20protection%20through%20their%20immunoregulatory%20and%20paracrine%20action%20has%20been%20reviewed%20extensively.%20However%2C%20the%20importance%20of%20process%20control%20to%20achieve%20a%20consistent%20cell%20quality%2C%20maximum%20safety%20and%20efficacy%20-%20for%20which%20the%20three%20key%20questions%20are%20of%20%5Cu2018which%27%2C%20%5Cu2018when%27%20and%20%5Cu2018how%20much%27%20-%20remain%20unaddressed.%20Any%20commonality%2C%20if%20exists%2C%20in%20the%20ongoing%20clinical%20trials%20is%20yet%20to%20be%20analysed%20and%20reviewed.%20In%20this%20review%2C%20we%20have%20therefore%20compiled%20and%20discussed%20study%20design%20data%20from%20ongoing%20clinical%20trials%20to%20address%20the%20key%20questions%20of%20%5Cu2018which%27%20tissue%20source%2C%20donor%20profile%2C%20isolation%20technique%2C%20culture%20conditions%2C%20long-term%20culture%20and%20cryopreservation%20for%20MSCs%3B%20the%20question%20of%20%5Cu2018when%27%20with%20regard%20to%20defining%20the%20transplantation%20window%2C%20by%20identifying%20and%20staging%20of%20patients%20based%20on%20their%20pro-inflammatory%20profile%3B%20and%20finally%20that%20of%20%5Cu2018how%20much%27%20with%20respect%20to%20the%20number%20of%20cells%20in%20a%20single%20administration%2C%20the%20number%20of%20doses%20and%20route%20of%20transplantation.%20To%20homogenize%20MSC%20therapy%20for%20COVID-19%20on%20a%20global%20scale%20and%20to%20make%20it%20readily%20available%20in%20large%20numbers%2C%20a%20shared%20understanding%20and%20uniform%20agreement%20on%20these%20fundamental%20issues%20is%20essential.%3C%5C%2Fp%3E%22%2C%22date%22%3A%222021%5C%2F04%5C%2F29%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jcyt.2021.04.004%22%2C%22ISSN%22%3A%221465-3249%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.isct-cytotherapy.org%5C%2Farticle%5C%2FS1465-3249%2821%2900234-6%5C%2Fabstract%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-05-04T17%3A40%3A49Z%22%7D%7D%5D%7D
Shahani, P., & Datta, I. (2021). Mesenchymal Stromal Cell therapy for COVID-19: Which? When? And How Much? Cytotherapy, 0(0). https://doi.org/10.1016/j.jcyt.2021.04.004 Cite
